Xinteza API

Company Overview

Snapshot

Founded in March 2019 by Alon Gal, Ron Klein, and Zohar Koren, Xinteza API operates with 1–10 employees. The company has secured one disclosed funding round and holds an exclusive license for cannabinoids and psychoactives from the Weizmann Institute, building a portfolio of related IP and patents.

Business overview

Xinteza API specializes in developing advanced proprietary biosynthesis and bioextraction technologies for producing cannabinoid-based active pharmaceutical ingredients (APIs) for the pharmaceutical and food industries. The company focuses on researching and discovering new genes and genetic pathways for cannabinoid and psychoactive biosynthesis, developing corresponding bioproduction methods. Xinteza API operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Medical Cannabis markets.

Strategic signal

In February 2023, Xinteza API introduced true water-soluble cannabinoids biosynthesis, a development poised to revolutionize applications in beverages, cosmetics, and pharmaceuticals. This innovation signals the company's progress in addressing solubility challenges, potentially unlocking new market opportunities and enhancing product efficacy across various industries.

Company Intelligence Q&A

What is Xinteza API's core focus?

Xinteza API is focused on developing advanced proprietary biosynthesis and bioextraction technologies for the production of cannabinoid-based active pharmaceutical ingredients (APIs) for the pharmaceutical and food industries.

When was Xinteza API founded and by whom?

Xinteza API was founded in March 2019 by co-founders Alon Gal, Ron Klein, and Zohar Koren.

What significant technology did Xinteza API introduce in February 2023?

In February 2023, Xinteza API introduced true water-soluble cannabinoids biosynthesis, aiming to revolutionize applications in beverages, cosmetics, and pharmaceuticals.

What was a key development announced by Xinteza API in September 2022?

In September 2022, Xinteza API introduced a novel key enzyme designed to solve major bottlenecks in cannabinoid biosynthesis.

Has Xinteza API received any investments?

In January 2020, IM Cannabis expanded its innovation portfolio with an investment in Xinteza API to develop innovative biosynthesis technology based on Weizmann Institute research.